Tertiary endpoints
Prurigo, ’, Skin Pain, herpetic infections, skin-infection TEAEs, NRS
PRURIGO

Use of high-potency or super-potent TCS rescue medication through week 24Use of systemic immunosuppressant through week 24, constituting treatment failureChange from baseline in HADS total score to week 24Change from baseline in EuroQoL five-dimension questionnaire, five-level version (EQ-5D5L) single index score to week 24Change from baseline in EQ-5D visual analog scale to week 24Change from baseline in Skin Pain NRS to week 4, week 8, week 12 and week 24, respectivelyChange from baseline in Sleep NRS to week 4, week 8, week 12 and week 24, respectivelyMissed school/workdays through week 24Incidence of skin-infection TEAEs (excluding herpetic infections) through week 24Proportion of patients who achieve ≥75% healed lesions from Prurigo Activity Score (PAS) at week 4, week 8, week 12 and week 24, respectivelyChange from baseline in exact number of lesions in representative area (as determined from PAS) at week 4, week 8, week 12 and week 24, respectivelyChange from baseline in Patient Global Impression of Severity (PGIS) of PN to week 4, week 8, week 12 and week 24, respectivelyProportion of patients with PGIS score of ‘none’ at week 4, week 8, week 12 and week 24, respectivelyProportion of patients with PGIS score of ‘none’ or ‘mild’ at week 4, week 8, week 12 and week 24, respectivelyPatient Global Impression of Change (PGIC) of PN at week 4, week 8, week 12 and week 24, respectivelyProportion of patients with PGIC score of ‘very much better’ at week 4, week 8, week 12 and week 24, respectively